{"id":"cggv:f3ae9a06-6429-4b4b-b008-e1454511d5bev1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:f3ae9a06-6429-4b4b-b008-e1454511d5be_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10023","date":"2021-06-16T14:46:32.357Z","role":"Approver"},{"id":"cggv:f3ae9a06-6429-4b4b-b008-e1454511d5be_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10023","date":"2021-06-16T14:46:42.841Z","role":"Publisher"}],"evidence":[{"id":"cggv:f3ae9a06-6429-4b4b-b008-e1454511d5be_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:f3ae9a06-6429-4b4b-b008-e1454511d5be_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:02d4bbac-0737-4e90-a197-702b618d39e0","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:527b9552-f16f-4b26-bfc4-3dc11fc91d89","type":"Finding","demonstrates":{"id":"cg:GeneExpressionB"},"dc:description":"Immunohistochemical analysis of the three PCCs carrying MAX mutations showed a lack of full-length MAX protein. The tumor DNA loss of the wild-type MAX allele in all three cases, indicating loss of heterozygosity (LOH).","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/21685915","type":"dc:BibliographicResource","dc:abstract":"Hereditary pheochromocytoma (PCC) is often caused by germline mutations in one of nine susceptibility genes described to date, but there are familial cases without mutations in these known genes. We sequenced the exomes of three unrelated individuals with hereditary PCC (cases) and identified mutations in MAX, the MYC associated factor X gene. Absence of MAX protein in the tumors and loss of heterozygosity caused by uniparental disomy supported the involvement of MAX alterations in the disease. A follow-up study of a selected series of 59 cases with PCC identified five additional MAX mutations and suggested an association with malignant outcome and preferential paternal transmission of MAX mutations. The involvement of the MYC-MAX-MXD1 network in the development and progression of neural crest cell tumors is further supported by the lack of functional MAX in rat PCC (PC12) cells and by the amplification of MYCN in neuroblastoma and suggests that loss of MAX function is correlated with metastatic potential.","dc:creator":"Comino-Méndez I","dc:date":"2011","dc:title":"Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma."},"rdfs:label":"Immunohistochemical analysis"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":1.5,"dc:description":"Tumors from 3 families with 3 different LoF variants showed no MAX expression and LOH."}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5},{"id":"cggv:f3ae9a06-6429-4b4b-b008-e1454511d5be_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:5721f1fe-0d5c-446e-ab8c-208800c5b896","type":"EvidenceLine","calculatedScore":0.5,"direction":"Inconclusive","evidence":[{"id":"cggv:f596859e-25a3-4e15-b3be-472a29c55a20","type":"FunctionalAlteration","dc:description":"Non truncating missense variants of MAX gene showed relative higher luciferase activity in Luciferase-reporter assays compared with a truncated null MAX protein or the wt MAX alone in PC12 cells due to their dominant negative activity.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/26070438","type":"dc:BibliographicResource","dc:abstract":"The presence of germline mutations affecting the MYC-associated protein X (MAX) gene has recently been identified as one of the now 11 major genetic predisposition factors for the development of hereditary pheochromocytoma and/or paraganglioma. Little is known regarding how missense variants of unknown significance (VUS) in MAX affect its pivotal role in the regulation of the MYC/MAX/MXD axis. In the present study, we propose a consensus computational prediction based on five \"state-of-the-art\" algorithms. We also describe a PC12-based functional assay to assess the effects that 12 MAX VUS may have on MYC's E-box transcriptional activation. For all but two of these 12 VUS, the functional assay and the consensus computational prediction gave consistent results; we classified seven variants as pathogenic and three as nonpathogenic. The introduction of wild-type MAX cDNA into PC12 cells significantly decreased MYC's ability to bind to canonical E-boxes, while pathogenic MAX proteins were not able to fully repress MYC activity. Further clinical and molecular evaluation of variant carriers corroborated the results obtained with our functional assessment. In the absence of clear heritability, clinical information, and molecular data, consensus computational predictions and functional models are able to correctly classify VUS affecting MAX.","dc:creator":"Comino-Méndez I","dc:date":"2015","dc:title":"Functional and in silico assessment of MAX variants of unknown significance."},"rdfs:label":"Cell culture and luciferase assays"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0,"dc:description":"9 out of 12 VUS missense variants consistently showed relative higher luciferase activity in Rat PC12 cell line. These 9 VUS variants affect conserved or highly conserved amino acids located within the basic helix-loop-helix leucine zipper (bHLH Zip) domain of the MAX protein. \nThe missense dominant negative is not the major mechanism of the disease and this experiment didn't show the direct relationship with tumor."}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0},{"id":"cggv:f3ae9a06-6429-4b4b-b008-e1454511d5be_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:6f779a0e-f06c-4421-bbe7-5ca58bc6d43d","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:f900c3de-1e61-4c30-a5ad-0acdadec5238","type":"Finding","demonstrates":{"id":"cg:PhenotypeRescue"},"dc:description":"Reintroduction of max into PC12 cells results in a reduction in growth rate, which may explain the\nloss of Max expression either during the growth of the pheochromocytoma or in subsequent passage of the PC12 cell line in vitro.  \n","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/7791753","type":"dc:BibliographicResource","dc:abstract":"Heterodimerization of Max with the nuclear oncoprotein Myc and the differentiation-associated proteins Mad and Mxi1 enables these factors to bind E-box sites in DNA and control genes implicated in cell proliferation and differentiation. We show that in the PC12 pheochromocytoma tumor cell line, functional Max protein is not expressed because of the synthesis of a mutant max transcript. This transcript encodes a protein incapable of homo- or heterodimerization. Furthermore, the mutant Max protein, unlike wild-type Max, is incapable of repressing transcription from an E-box element. Synthesis of mutant max transcripts appears to be due to a homozygous chromosomal alteration within the max gene. Reintroduction of max into PC12 cells results in repression of E-box-dependent transcription and a reduction in growth rate, which may explain the loss of Max expression either during the growth of the pheochromocytoma or in subsequent passage of the PC12 cell line in vitro. Finally, the ability of these cells to divide, differentiate, and apoptose in the absence of Max demonstrates for the first time that these processes can occur via Max- and possibly Myc-independent mechanisms.","dc:creator":"Hopewell R","dc:date":"1995","dc:title":"The nerve growth factor-responsive PC12 cell line does not express the Myc dimerization partner Max."},"rdfs:label":"Cell culture and growht rate"}],"specifiedBy":"GeneValidityCellCultureRescueCriteria","strengthScore":1},{"id":"cggv:80a51a2b-28e8-4741-8729-49b5093e03a3","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"cggv:6bfad952-77e5-4731-8236-7c6007d0c630","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"PC12 is a cell line derived from a pheochromocytoma of the rat adrenal medulla. Normal Max protein is not expression in PC12 cells. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7791753","rdfs:label":"Northern blots"}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":1,"dc:description":"The PC12 pheochromocytoma tumor cell line, functional Max protein is not expressed because of the synthesis of a mutant max transcript. This transcript encodes a protein incapable of homo- or heterodimerization"}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3.5},{"id":"cggv:f3ae9a06-6429-4b4b-b008-e1454511d5be_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:f3ae9a06-6429-4b4b-b008-e1454511d5be_ad_null_el","type":"EvidenceLine","evidence":[{"id":"cggv:b57d35c3-054a-446f-a099-7864e033c34f_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:05a54275-8062-433a-ae55-8ec29f9fa767","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":40,"ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"PCR","phenotypeFreeText":"Bilateral PCC and thoracoabdominal PGL","phenotypes":["obo:HP_0002666","obo:HP_0002668"],"previousTesting":true,"previousTestingDescription":"negative for RET, VHL, SDHB, SDHC, SDHD, and TMEM127 genes","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:b57d35c3-054a-446f-a099-7864e033c34f_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:e1cdfb64-80ff-42b3-800a-5cb3ba683620","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002382.5(MAX):c.295+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA196421"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/22452945","type":"dc:BibliographicResource","dc:abstract":"Pheochromocytomas (PCC) and paragangliomas (PGL) are genetically heterogeneous neural crest-derived neoplasms. Recently we identified germline mutations in a new tumor suppressor susceptibility gene, MAX (MYC-associated factor X), which predisposes carriers to PCC. How MAX mutations contribute to PCC/PGL and associated phenotypes remain unclear. This study aimed to examine the prevalence and associated phenotypic features of germline and somatic MAX mutations in PCC/PGL.","dc:creator":"Burnichon N","dc:date":"2012","dc:title":"MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/22452945","rdfs:label":"18"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"cggv:0d4e7191-0b2c-4de1-88f2-a4a7dfd988e9_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:fa548866-42be-404f-b2cf-d71f90681df0","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":46,"ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Bilateral","phenotypes":"obo:HP_0002666","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:0d4e7191-0b2c-4de1-88f2-a4a7dfd988e9_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:bd263be0-1711-4f7b-9fac-d9877262fc64","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002382.5(MAX):c.1A>G (p.Met1?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA128636"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21685915"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21685915","rdfs:label":"924"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"cggv:f7552d60-ca31-4617-8e1c-de78e62d455e_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:d92e105d-dcea-4f68-82a4-a0d1c18930ab","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":29,"detectionMethod":"Seven HapMap individuals (three males and four females) as quality and filtering controls","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Bilateral","phenotypes":"obo:HP_0002666","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:f7552d60-ca31-4617-8e1c-de78e62d455e_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:14de950a-632d-41af-a749-3f69065aa22d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002382.5(MAX):c.223C>T (p.Arg75Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA128639"}},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21685915"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21685915","rdfs:label":"3121"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":2,"dc:description":"This variant is reported in at least 4 sporadic cases (bilateral PCC) from Germany 2), and Poland (2) [PMID: 28384794]"},{"id":"cggv:66c4600b-1d43-4b5b-9dcf-82d48fb3c5bc_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:d099b2df-700d-4f2c-9150-bb2f03f56c48","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":17,"ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Bilateral","phenotypes":"obo:HP_0002666","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:66c4600b-1d43-4b5b-9dcf-82d48fb3c5bc_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:c9a18b63-8d5e-4383-ba1a-a70e762cacdf","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002382.5(MAX):c.97C>T (p.Arg33Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA128642"}},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21685915"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21685915","rdfs:label":"190"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":2,"dc:description":"8 cases reported in other cohort [PMID: 22452945]"},{"id":"cggv:b314c590-9743-4018-8db4-8543c45755ce_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:30aed9b0-393f-4bbc-87be-14a34bf5aa96","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":32,"ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Bilateral","phenotypes":"obo:HP_0002666","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:b314c590-9743-4018-8db4-8543c45755ce_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:e1cdfb64-80ff-42b3-800a-5cb3ba683620"},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21685915"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21685915","rdfs:label":"3037"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"cggv:e882f446-de72-454a-be6a-80dbb3b136b3_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:3551f843-3ae7-4e63-b89a-f55e2e04f0e6","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":47,"ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Bilateral","phenotypes":"obo:HP_0002666","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:e882f446-de72-454a-be6a-80dbb3b136b3_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:ba853fbf-2731-400a-ad84-1c5c38a3e180","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002382.5(MAX):c.187del (p.Ile63SerfsTer2)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/29789"}},"alleleOrigin":{"id":"obo:GENO_0000888"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21685915"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/21685915","rdfs:label":"1016"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallAutosomalDominantNullVariantEvidenceCriteria","strengthScore":10},{"id":"cggv:f3ae9a06-6429-4b4b-b008-e1454511d5be_ad_dn_el","type":"EvidenceLine","evidence":[{"id":"cggv:70d3b644-f8cd-495b-ae02-83f659b05487_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:da635212-fba3-4cfd-bb4e-33689c600353","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":26,"detectionMethod":"MLPA","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"bilateral adrenal","phenotypes":"obo:HP_0002666","previousTesting":true,"previousTestingDescription":"Genetic testing on NF, VHL, SDHA, SDHB, SDHC, SDHD, SDHAF2 and TMEM127 using Sanger sequencing and MLPA","secondTestingMethod":"Other","sex":"Male","variant":{"id":"cggv:70d3b644-f8cd-495b-ae02-83f659b05487_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:0e011530-093f-4a46-8577-333c5b344468","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002382.5(MAX):c.307G>T (p.Glu103Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA390031997"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/28384794","type":"dc:BibliographicResource","dc:abstract":"Effective cancer prevention is based on accurate molecular diagnosis and results of genetic family screening, genotype-informed risk assessment, and tailored strategies for early diagnosis. The expanding etiology for hereditary pheochromocytomas and paragangliomas has recently included SDHA, TMEM127, MAX, and SDHAF2 as susceptibility genes. Clinical management guidelines for patients with germline mutations in these 4 newly included genes are lacking.","dc:creator":"Bausch B","dc:date":"2017","dc:title":"Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28384794","rdfs:label":"6"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallAutosomalDominantDeNovoVariantEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":2959,"specifiedBy":"GeneValidityCriteria8","strengthScore":15.5,"subject":{"id":"cggv:6ae8a3bc-d973-4114-b221-af842a98aba6","type":"GeneValidityProposition","disease":"obo:MONDO_0017366","gene":"hgnc:6913","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","dc:description":"Hereditary Paraganglioma-Pheochromocytoma Syndromes (PGL/PCC) [MONDO:0017366, PMID: 20301715] describes susceptibility to pheochromocytoma and paraganglioma with autosomal dominant inheritance. The MAX gene [MIM# 154950] -MYC associated factor X- is one of the susceptibility genes resulting  in genetic predisposition to PCC, mostly in patients without familial antecedents, probably due to a paternal transmission effect [PMID 21685915 and 22452945]. MAX was first reported in relation to PGL/PCC in 2011 [Comino-Méndez I et al., PMID: 21685915]. Genetic evidence includes loss of function and missense variants in MAX found in Hereditary PCC with missense variants likely being the dominant negative effect [PMID: 26070438]. Genetic evidence was scored for loss of function variants [PMID 21685915, 22452945 and 28384794]. Missense variants and deletions are also reported but not used for this curation [PMID: 26670126 and 23666964]. Experimental evidence demonstrated loss MAX gene expression and loss of heterozygosity (LOH) in patient tumors carrying LoF variants [PMID: 21685915]. Loss of functional MAX expression in a Rat Pheochromocytoma (PCC) cell line (PC12) and reduction of cell proliferation by reintroducing MAX expression [PMID: 7791753], which showed MAX is a tumor suppressor gene. Luciferase reporter activity assays with 9 missense variants confirmed the dominant negative mechanism in pathogenesis of hereditary PCC [PMID: 26070438]. The encoded MAX protein is the most conserved dimerization component of the MYC-MAX-MXD1 network of basic helix-loop-helix leucine zipper (bHLHZ) transcription factors that regulate cell proliferation, differentiation, and apoptosis. MAX is definitely associated with autosomal dominant HPGL/PCC syndrome, most commonly pheochromocytoma. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.","dc:isVersionOf":{"id":"cggv:f3ae9a06-6429-4b4b-b008-e1454511d5be"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}